Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722928 | 0.90 | KDM4E (0.51) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723228 | 0.86 | KDM4E (0.48) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723212 | 0.86 | KDM4E (0.50) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL24923398 | 0.84 | GLA (0.55) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723149 | 0.84 | MAPT (0.54) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723197 | 0.82 | GLA (0.47) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20722905 | 0.81 | MAPT (0.43) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20722940 | 0.81 | MAPT (0.43) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723084 | 0.80 | KDM4E (0.52) | KDM4EMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20723012 | 0.80 | KDM4E (0.45) | KDM4EMAPTMAPK1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3664806-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-06-17 | — | — | EP | claimed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | claimed |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210040098-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-02-11 | — | — | US | disclosed |
| EP-3664806-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | APLNR, AP3B1, AGTR1 | KDM4E 4400/4885MAPT 3809/4885ALDH1A1 736/4885 |
| US-20210040098-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | KDM4E 4688/4885MAPT 4138/4885ALDH1A1 1590/4885 |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | APLNR, AP3B1, AGTR1 | KDM4E 4400/4885MAPT 3809/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.